ASX Announcement 17 November 2026 Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer Highlights ? Rhythm has appointed Adam Zembrzuski as Chief Commercial Officer (CCO), effective 18 November 2026 ? Adam brings 21 years’ commercial leadership experience in clinical diagnostics, medical...
Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has appointed Adam Zembrzuski as Chief Commercial Officer, effective soon. Mr. Zembrzuski brings extensive experience in clinical diagnostics and will lead the company's global commercial growth strategy. His role includes overseeing the commercial strategy for existing products and expanding market access. The announcement highlights the company's focus on accelerating revenue growth and increasing clinical adoption of its diagnostic platforms.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Commercial Update-Expansion of ColoSTAT ordering capability
- RHY Q1 FY27 Update
- Quarterly Activities Report and Appendix 4C
- Notice of Annual General Meeting/Proxy Form
- ColoSTAT Economic Study - Australian Public Health Savings
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences